Clinical trials: Esophagogastric Junction Disorder
Gastric Cancer (GC), Gastroesophageal Junction Adenocarcinoma
Chemoradiotherapy and SHR-1701 in Patients With Unresectable Gastric Cancer
Gastric Cancer is one of the leading causes of cancer-related death worldwide, and patients with unresectable locally advanced or metastatic disease have a poor prognosis.
- Trial name
- NCT07689851
- Testing
- COPOX, Radiotherapy, SHR-1701
- Where
- 3 sites in China
- Volunteers
- 60 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Relapsed or Advanced Gastric Adenocarcinoma, Gastro-esophageal Junction Cancer
Investigator-initiated Pilot Study to Investigate the Efficacy and Safety of Immuncell-LC in Combination With Nivolumab (Opdivo) in Subjects With Advanced or Recurrent Gastric Cancer
This study was planned to evaluate the efficacy and safety of combination therapy of Immuncell-LC and nivolumab in patients with relapsed or advanced gastric adenocarcinoma or gastro-esophageal junction cancer.
- Trial name
- NCT05053295
- Testing
- autologous activated T lymphocyte
- Where
- South Korea
- Volunteers
- 20 people
- Sponsor
- Gangnam Severance Hospital
Cancer of the Esophagus
Timing of Resective Surgery After Neoadjuvant Chemoradiotherapy in Esophageal Cancer
This study compares outcomes with regard to the timing of resective surgery after neoadjuvant chemoradiotherapy (CRT) in cancer of the esophagus or gastric cardia.
- Trial name
- NeoResII (NCT02415101)
- Testing
- Resective surgery
- Where
- Sweden
- Volunteers
- 202 people
- Sponsor
- Karolinska University Hospital
Gastric Cancer, GastroEsophageal Cancer
A Study of SHR-1210 in Combination With Capecitabine + Oxaliplatin or Apatinib in Treatment of Advanced Gastric Cancer
The purpose of this trial is to estimate overall response rate (ORR) of SHR-1210 combined with capecitabine and oxaliplatin or with apatinib as first-line treatment in subjects with locally advanced or metastatic gastric or…
- Trial name
- NCT03472365
- Testing
- SHR-1210, Capecitabine, Oxaliplatin
- Where
- China
- Volunteers
- 67 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Adenocarcinoma of the Gastroesophageal Junction, Diffuse Adenocarcinoma of the Stomach
Phase II Study of Oxaliplatin, Irinotecan, and Capecitabine in Advanced Gastric/Gastroesophageal Junction Carcinoma
Drugs used in chemotherapy, such as oxaliplatin, irinotecan, and capecitabine, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Conditions
- Adenocarcinoma of the Gastroesophageal Junction, Diffuse Adenocarcinoma of the Stomach, Intestinal Adenocarcinoma of the Stomach, Mixed Adenocarcinoma of the Stomach
- Trial name
- NCT00084617
- Testing
- oxaliplatin, irinotecan hydrochloride, capecitabine
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- National Cancer Institute (NCI)
Ovarian Carcinoma, Fallopian Tube Carcinoma
NM32-2668 in Adult Patients With Selected Advanced Solid Tumors
This is a first-in-human, open-label, multi-center, Phase 1, dose-escalation study with expansion cohorts to evaluate NM32-2668 for safety and immunogenicity, to determine the maximal tolerated dose and recommended Phase 2 dose…
- Conditions
- Ovarian Carcinoma, Fallopian Tube Carcinoma, Peritoneal Carcinoma, Endometrial Cancer
- Trial name
- NCT06299163
- Testing
- NM32-2668
- Where
- 11 sites in United States
- Volunteers
- 11 people
- Sponsor
- Numab Therapeutics AG
Cancer-associated Thrombosis, Esophageal Cancer
A Randomized Phase II Open Label Study to Compare the Safety and Efficacy of Subcutaneous Dalteparin Versus Direct Oral Anticoagulants for Cancer-associated Venous Thromboembolism
This is an open label, multi-center, and randomized phase II trial designed to compare the safety and efficacy of direct oral anticoagulants and subcutaneous dalteparin in patients with acute venous thromboembolism and upper…
- Conditions
- Cancer-associated Thrombosis, Esophageal Cancer, Stomach Cancer, Hepatocellular Carcinoma
- Trial name
- PRIORITY (NCT03139487)
- Testing
- Rivaroxaban, Dalteparin, apixaban
- Where
- South Korea
- Volunteers
- 176 people
- Sponsor
- Asan Medical Center
Endometrial Cancer, Cervical Cancer
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-M07D1 in patients with HER2 expressing advanced tumors.
- Conditions
- Endometrial Cancer, Cervical Cancer, Ovarian Cancer, Urothelial Carcinoma
- Trial name
- NCT06293898
- Testing
- BL-M07D1
- Where
- 26 sites in United States
- Volunteers
- 280 people
- Sponsor
- SystImmune Inc.
Gastro Esophageal Junction Cancer, Stomach Cancer
Perioperative mFOLFOX Plus Pembrolizumab in Gastroesophageal Junction (GEJ) and Stomach Adenocarcinoma
To evaluate the antitumor activity and safety/tolerability of the combination (mFOLFOX + Pembrolizumab) in patients with potentially resectable adenocarcinoma of the Gastroesophageal Junction (GEJ) and stomach.
- Conditions
- Gastro Esophageal Junction Cancer, Stomach Cancer, Adenocarcinoma
- Trial name
- NCT03488667
- Testing
- Neoadjuvant Treatment - mFOLFOX6 & Pembrolizumab, Adjuvant Treatment - mFOLFOX & Pembrolizumab
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Kansas Medical Center
Metastatic Colorectal Cancer, Gastric Cancer
Vactosertib in Combination with Pembrolizumab in Metastatic Colorectal or Gastric Cancer
This is an open-label, multicenter study to assess the safety, tolerability, pharmacokinetics, and antitumor activity of vactosertib in combination with pembrolizumab in patients with metastatic or locally advanced colorectal or…
- Conditions
- Metastatic Colorectal Cancer, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
- Trial name
- NCT03724851
- Testing
- TEW-7197
- Where
- 5 sites in South Korea
- Volunteers
- 120 people
- Sponsor
- MedPacto, Inc.
Adenocarcinoma of the Gastroesophageal Junction, Esophageal Adenocarcinoma
Panitumumab, Combination Chemotherapy, & Radiation Therapy in Esophageal or Gastroesophageal Junction Cancer
This phase II trial is studying how well giving panitumumab, combination chemotherapy, and radiation therapy together before surgery works in treating patients with advanced esophageal or gastroesophageal (GE) junction cancer.
- Conditions
- Adenocarcinoma of the Gastroesophageal Junction, Esophageal Adenocarcinoma, Stage IIA Esophageal Cancer, Stage IIB Esophageal Cancer
- Trial name
- NCT01307956
- Testing
- Fluorouracil, Laboratory Biomarker Analysis, Leucovorin Calcium
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of Nebraska
Gastroesophageal Junction Adenocarcinoma, Stomach Neoplasms
Phase II Study of Avelumab Plus Chemotherapy in the Peri-operative Treatment for Patients With Resectable Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJC)
Phase II Study of Avelumab plus chemotherapy in the peri-operative treatment for patients with resectable Gastric cancer (GC) or Gastroesphageal Junction cancer (GEJC) The addition of Avelumab to the perioperative chemotherapy in…
- Trial name
- MONEO (NCT03979131)
- Testing
- Avelumab addition to perioperative chemotherapy in GC and GEJC
- Where
- Spain
- Volunteers
- 40 people
- Sponsor
- Vall d'Hebron Institute of Oncology
Gastric Cancer, Gastroesophageal Junction Cancer
A Prospective Cohort Study on the Treatment of Locally Advanced Gastric Cancer
The clinical trial aims to assess the efficacy and safety of Tislelizumab combined with the SOX regimen and HIPEC in treating locally advanced gastric cancer.
- Trial name
- NCT06760858
- Testing
- Tislelizumab, SOX, HIPEC
- Where
- 2 sites in China
- Volunteers
- 122 people
- Sponsor
- Southwest Hospital, China
Stomach Neoplasms, Siewert Type II Adenocarcinoma of Esophagogastric Junction
Length of the Proximal Resection Margin for Siewert-II/Siewert-III Tumors
The incidence of adenocarcinomas of the esophagogastric junction (AEJ) has increased rapidly during the past decades. By the Siewert classification, the AEJ is the tumor center located 5 cm above the anatomic cardia and 5 cm…
- Conditions
- Stomach Neoplasms, Siewert Type II Adenocarcinoma of Esophagogastric Junction, Recurrence, Siewert Type III Adenocarcinoma of Esophagogastric Junction
- Trial name
- NCT02313688
- Testing
- gastrectomy
- Where
- China
- Volunteers
- 320 people
- Sponsor
- West China Hospital
Gastric Cancer
A Phase II Study of Carelizumab Combined With Irinotecan and Apatinib of Second-line Treatment for Advanced Gastric Cancer
The purpose of this study was to evaluate the overall survival time (OS), objective remission rate（ORR）, progression-free survival time（PFS）, disease control rate（DCR）of Carelizumab combined with irinotecan and apatinib for the…
- Trial name
- NCT04934618
- Testing
- Carelizumab Combined With Irinotecan and Apatinib
- Where
- China
- Volunteers
- 85 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Study of T-DXd Monotherapy in Patients With HER2-expressing Locally Advanced or Metastatic Gastric or GEJ Adenocarcinoma Who Have Received 2 or More Prior Regimens
This is a Phase II, open-label, single-arm, multicentre, study in China assessing the efficacy and safety of T-DXd in participants with HER2-expressing advanced gastric or GEJ adenocarcinoma who have received at least 2 prior…
- Trial name
- DG-06 (NCT04989816)
- Testing
- Trastuzumab Deruxtecan
- Where
- 24 sites in China
- Volunteers
- 95 people
- Sponsor
- AstraZeneca
Gastric Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Docetaxel, Oxaliplatin, and Fluorouracil in Treating Patients With Metastatic or Unresectable Stomach Cancer, Gastroesophageal Junction Cancer, or Other Solid Tumor
RATIONALE: Drugs used in chemotherapy, such as docetaxel, oxaliplatin, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00711243
- Testing
- docetaxel, fluorouracil, oxaliplatin
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- Northwestern University
Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction
Erlotinib Hydrochloride in Treating Patients With Advanced Esophageal Cancer or Stomach Cancer
This phase II trial is studying erlotinib hydrochloride to see how well it works in treating patients with advanced esophageal cancer or stomach cancer.
- Conditions
- Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction, Recurrent Esophageal Cancer, Squamous Cell Carcinoma of the Esophagus
- Trial name
- NCT00045526
- Testing
- erlotinib hydrochloride, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- National Cancer Institute (NCI)
Gastric Cancer
OGT-assisted Overlap Esophagojejunostomy Versus Traditional Overlap Method
Abstract Background Our previous studies have shown OGT method significantly simplified overlap esophagojejunostomy with good short-term outcomes, and provided new perspectives for optimizing esophagojejunostomy.
- Trial name
- OGT (NCT05450835)
- Testing
- OGT group, Overlap group
- Where
- 12 sites in China
- Volunteers
- 344 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Gastro Esophageal Reflux
Validation of HRM Score for the GERD Diagnosis
The goal of this prospective study is to validate a high resolution manometry score to predict pathologic GERD in patients with reflux symptoms.
- Trial name
- HRM nomogram (NCT05851482)
- Testing
- High resolution manometry
- Where
- Italy
- Volunteers
- 246 people
- Sponsor
- IRCCS Policlinico S. Donato